Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review

References

• Cardoso F, Harbeck N, Fallowfield L, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19
   PubMed Web of Science ®Google Scholar
• Stockler M, Sourjina T, Grimison P, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). Proceedings of 2007 American Society of Clinical Oncology Annual Meeting; Chicago J Clin Oncol 2007. 25(Suppl 18):1031
   Google Scholar
• Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54
   PubMed Web of Science ®Google Scholar
• Blum JL, Dieras V, Lo Russo P, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92(7):1759-68
   PubMed Web of Science ®Google Scholar
• Awada A, Aftimos PG. Targeted therapies of solid cancers: new options, new challenges. Curr Opin Oncol 2013;25(3):296-304
   Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortès J, Kim SB, et al. CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25(33):5210-17
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Shaughnessy J, Loesch D, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377(9769):14-923
   Google Scholar
• Nektar Therapeutics. The BEACON Study (Breast Cancer Outcomes With NKTR-102). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01492101&Search=Search [Last accessed 16 June 2013]
   Google Scholar
• O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20(12):2812-23
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26(24):3950-7
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10(1):123-30
   PubMed Web of Science ®Google Scholar
• Hirata Y, Uemura D. Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58(5):701-10
   Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4(7):1086-95
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64:5760-6
   PubMed Web of Science ®Google Scholar
• Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006;70(6):1866-75
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, Ten Dyke K, Yu MJ, Littlefield BA. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxelresistant human cancer cells in vitro. [ abstract In: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007 San Francisco, CA, USA. Proc Am Assoc Cancer Res. 2007.48:275. Abstract C58 Available at www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2007/3_Molecular_Targets_Meeting/C58?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=kuznetsov&searchid=1&FIRSTINDEX=0&volume=2007&issue=3_Molecular_Targets_Meeting&resourcetype=HWCIT
   Google Scholar
• Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase iii studies and a critical reappraisal of available evidence. J Oncol 2012;2012:417673
   PubMedGoogle Scholar
• Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;133(3):1067-75
   PubMed Web of Science ®Google Scholar
• Thomssen C, Pierga JY, Pritchard K, et al. First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology 2012;82(4):218-27
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461-71
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-103
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady M, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Nab-Paclitaxel Plus Gemcitabine in Pancreatic Cancer. Gastrointestinal Cancers Symposium; abstract LBA148 25 January 2012; San Franscisco
   Google Scholar
• Vermorken JB, Remenar E, van Herpen C, et al. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20(4):937-40
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20(12):2824-31
   PubMed Web of Science ®Google Scholar
• Uemura D, Takahashi K, Yamamoto T, et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985;107(16):4796-8
   Web of Science ®Google Scholar
• Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol 2012;81(2):163-84
   PubMed Web of Science ®Google Scholar
• Hirata Y, Uemura D. Halichondrins—antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58(5):701-10
   Web of Science ®Google Scholar
• Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61(3):1013-21
   PubMed Web of Science ®Google Scholar
• Luduena RF, Roach MC, Prasad V, Pettit GR. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 1993;45(2):421-7
   Google Scholar
• Yu M, Littlefield B, Kishi Y. Discovery of E7389, a fully synthetic macrocyclic ketone analog of Halichondrin B. In: Anticancer agents from natural products. CRC Press; 2005
   Google Scholar
• Halaven [package insert]. Eisai Inc, Woodcliff Lake, NJ, USA; 2010
   Google Scholar
• Luyimbazi D, Luu T, Xing Q. A comparaison of PI3K inhibition by eribulin, other microtubule targeting agents and a DNA-damaging chemotherapeutic in triple negative and her2 breast cancer cell lines. Proceeding San Antonio Breast Cancer 2013; P3-03-08 12 December 2013
   Google Scholar
• Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivi anticancer activities of synthetic macrocyclinic ketone analogues of Halochondrin B. Cancer Res 2001;61(3):1013-21
   PubMed Web of Science ®Google Scholar
• Pean E, Klaar S, Berglund EG, et al. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 2012;18(17):4491-7
   PubMed Web of Science ®Google Scholar
• Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15(12):4207-12
   PubMed Web of Science ®Google Scholar
• Synold TW, Morgan RJ, Newman EM, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. 2005 ASCO Annual Meeting Proceedings; J Clin Oncol 2005. 23(16S):3036
   Google Scholar
• Witteveen P, Marchetti S, Mergui-Roelvink M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol 2010. 28(Suppl 15):2582; Abst2582
   Google Scholar
• Jansen M, Vernaz-Gris M, DesJardins C, et al. Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC). 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol 2009. 27(15S; abstract 2524
   Google Scholar
• Devriese LA, Wanders J, Jenner A, et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Proceedings of the AACR Symposium; 2010; abstract 574
   Google Scholar
• Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15(12):4213-19
   PubMed Web of Science ®Google Scholar
• Minami H, Mukohara T, Nagai S, et al. A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer 2008(Suppl 6):140; abstract 446
   Web of Science ®Google Scholar
• Synold TW, Tsao-Wei DD, Quinn DI, et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium Trial. Abstract 2527 J Clin Oncol 2010;28(Suppl):7s
   Google Scholar
• Goel R, Chen E, Welch S, et al. Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol 2009;27(Suppl; Abstract e13509
   Google Scholar
• Swami U, Petrylak DP, Raftopoulos H, et al. Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol 2009. 28(Suppl 15; abst 2589
   Google Scholar
• Mukai H, Shimada K, Naito et al. A phase I combination Study of eribulin Mesylate with Trastuzumab for Advanced or Recurrent Her2+ Breast cancer ESMO 2013. abstract 1898
   Google Scholar
• Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27(18):2954-61
   PubMed Web of Science ®Google Scholar
• Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28(25):3922-8
   PubMed Web of Science ®Google Scholar
• Aogi K, Iwata H, Masuda N. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012;23(6):1441-8
   PubMed Web of Science ®Google Scholar
• Vahdat L, Garcia AA, et al. Eribulin mesylate versus ixabepilone in metastatic breast cancer patients: a randomized phase ii study comparing the incidence of peripheral neuropathy. Breast Cancer ResTreat 2013;140(2):341-51
   PubMed Web of Science ®Google Scholar
• McIntyre K, O’Shaughenessy J, Schwartzberg L, et al. Eribulin mesylate as first line therapy for locally recurrent or metastatic HER2 negative breast cancer: results of a phase 2, multicenter, single-arm study. Proceedings of the 2013 San Antonio Breast Cancer Symposium; abstract P3-13-05 12 December 2013
   Google Scholar
• Wilks S, Puhalla S, O’shaughnessy J, et al. Phase 2, multicenter, single arm study of Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Proceedings of the 2013 San Antonio Breast Cancer Symposium 2013; abstract P4-12-12 13 December 2013
   Google Scholar
• Traina TA, Hudis C, Fornier M, et al. Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility study. Proceedings of the 2012 San Antonio Breast Cancer Symposium; San Antonio, TX, USA, abstract P1-13-11 11 December 2012
   Google Scholar
• Smith J, Rege J, Meniar H, et al. Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal estrogen positive early stage breast cancer: Phase 2, multicenter, single center study. 2013 ASCO Annual Meeting Proceedings; J Clin Oncol 2013. 31; San Antonio, TX, USA, abstract 563
   Google Scholar
• Giordano SB, Jeruss JS, Bethke KP, et al. Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients. Proceedings of the 2013 San Antonio Breast Cancer Symposium; San Antonio, TX, USA, abstract P3-14-14 12 December 2013
   Google Scholar
• Spira AI, Iannotti NO, Savin MA, et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer 2012;13(1):31-8
   PubMed Web of Science ®Google Scholar
• de Bono JS, Molife LR, Sonpavde G, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012;23(5):1241-9
   PubMed Web of Science ®Google Scholar
• Stein MN, Chen Y, Hudes GR, et al. ECOG 5805: a phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol 2010. 28(Suppl 15):4556
   Google Scholar
• Renouf DJ, Tang PA, Major P, et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs 2012;30(3):1203-7
   Google Scholar
• Schöffski P, Ray-Coquard IL, Cioffi A, et al. European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011;12(11):1045-52
   PubMed Web of Science ®Google Scholar
• Hensley ML, Kravetz S, Jia X, et al. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer 2012;118(9):2403-10
   PubMed Web of Science ®Google Scholar
• Arnold SM, Moon J, Williamson SK. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: southwest Oncology Group trial S0618. Invest New Drugs 2011;29(2):352-9
   PubMed Web of Science ®Google Scholar
• Quinn DI, Aparicio A, Tsao-Wei DD, et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol 2010. 28(Suppl 15):4539
   Google Scholar
• E7389 versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00388726&Search=Search
   Google Scholar
• E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00337103&Search=Search
   Google Scholar
• Kaufmann PA, Awada A, Twelves C, et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res 2012;72(Suppl 24):S6-
   Google Scholar
• Kaufman PA, Yelle L, Cortes J, et al. Effect on age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. 2013 San Antonio Breast Cancer Symposium; abstract P3-13-04 12 December 2013
   Google Scholar
• McGarvey EL, Baum LD, Pinkerton RC, et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9(6):283-9
   PubMedGoogle Scholar
• Eisai Inc. An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01240421&Search=Search [Last accessed 23 June 2013]
   Google Scholar
• Eisai Co., Ltd. Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01463891&Search=Search [Last accessed 23 June 2013]
   Google Scholar
• Ruiz-Borrego M, Garcia-Saenz JA, Hornedo FJ, et al. First year daily clinical experience with eribulin in Spain; EUFORIA-1 study ESMO 2013. Abstract 1899
   Google Scholar
• Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110(5):965-72
   PubMed Web of Science ®Google Scholar
• de Graan AJ, Elens L, Sprowl JA, et al. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clin Cancer Res 2013;19(12):3316-24
   PubMed Web of Science ®Google Scholar
• Lopes G, Glück S, Avancha K, Montero AJ. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2013;137(1):187-93
   PubMed Web of Science ®Google Scholar
• to-BBB technologies B.V. An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01386580&Search=Search
   Google Scholar
• Yu Y, Desjardins C, Saxton P, et al. Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice. Int J Pharm 2013;443(1-2):9-16
   PubMedGoogle Scholar
• Oostendorp L, Stalmeier P, van der Graff W, Ottevanger P. Efficacy ans safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol 2011;12:1053-61
   PubMed Web of Science ®Google Scholar
• The BEACON study (Breast Cancer Outcomes with NKTR-102). Available from: www.clinicaltrials.gov/ct2/results?term=NCT01492101&Search=Search
   Google Scholar
• Smith BD, Kaufman MD, Hood MM, et al. Rebastinib in combination with eribulin ablates TIE2-expressing macrophages, reduces metastatis, and increases survival in the PyMT metastatic breast cancer model. (Abstract P4-15-12) Presented at San Antonio Breast Cancer. 13 December 2013
   Google Scholar
• Gitlitz BJ, Tsao-Wei DD, Groshen S, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol 2012;7(3):574-8
   PubMed Web of Science ®Google Scholar